GLP-3R

GLP-3R is a supplier-designated research construct in the incretin and metabolic signaling space, with no peer-reviewed literature on the construct itself.

Yes. 10 third party certificates for GLP-3R are published on this site, covering endotoxin, purity and sterility. Each one is the report as the testing laboratory issued it, not a retyped summary, and the most recent lot is 5mg · Jan 2026. Match the batch on your vial to the batch on the report.

Refrigerate (2-8 deg C) Lyophilized powder is the stable form; once reconstituted, a solution is far more fragile and should be aliquoted rather than repeatedly frozen and thawed.

>=99% by HPLC. The released figure for any given lot is on that lot's certificate rather than taken from this page, because purity is a property of a batch and not of a product line.

No. This is sold for laboratory research use only. It is not a drug, not a supplement, and not approved by the FDA for human or veterinary use. We do not provide dosing, administration, or protocol guidance, by phone, by email, or through the assistant on this site.

No. There is no GLP-3 receptor in human physiology, no corresponding gene, and no entry in IUPHAR receptor nomenclature. The recognized family is GLP1R, GIPR, and GCGR. GLP-3R is a supplier designation for a research construct, and the numeral references a multi-receptor design concept rather than a receptor subtype.

Because the composition is proprietary and undisclosed, there is no published sequence, molecular formula, molecular weight, or CAS number for this designation. Publishing invented values would be worse than publishing none. Researchers should obtain lot-specific analytical data rather than relying on catalog specifications.

None on this construct. No receptor binding data, no functional assay data, no pharmacokinetics, no animal studies, and no human data have been published for it. The peer-reviewed literature that exists concerns the incretin receptor family generally and specific, fully characterized molecules that are unrelated to this material.

No, other than as general background on receptor biology. Published polyagonist studies describe defined molecules with disclosed sequences and measured receptor affinities. Transferring those findings assumes an equivalence that has never been demonstrated for a construct of undisclosed composition.

A lot-specific certificate of analysis, a mass spectrometry profile identifying every component present rather than confirming a single expected mass, a reversed-phase HPLC trace showing relative abundance of each species, and a net peptide content figure accounting for water and counterion. Third-party testing on the received lot carries the most weight.

No. It is not an approved drug in any jurisdiction, has no published clinical development program, and is supplied for laboratory research use only. It is not equivalent to any commercial pharmaceutical product.